Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jonathan B. Basilla"'
Autor:
Jonathan B. Basilla, Christopher P. Davie, Richard M. Dunham, Feng Wang, David Favre, Jeffrey A. Messer, Zhengrong Zhu, Bing Xia, Yoshiaki Washio, Alison Olszewski, Wieslaw M. Kazmierski, Lijun Fan, Makda Mebrahtu, Ghotas Evindar, Hongfeng Deng, Vicente Samano, Liping Wang, Martha Alicia De La Rosa, Ninad V. Prabhu, John F. Miller
Publikováno v:
Journal of Medicinal Chemistry. 63:3552-3562
We report the discovery of a novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor class through the affinity selection of a previously unreported indole-based DNA-encoded library (DEL). The DEL exemplar, spiro-chromane 1, had moderate IDO1 potency bu
Autor:
Joseph P. Marino, Jonathan B. Basilla, David G. Washburn, Elizabeth A. Davenport, Jeff J. McAtee, Xiaoping Xu, Dan J. Gillie, Lamont Roscoe Terrell, Irina M. Lozinskaya, Christine G. Schnackenberg, Dennis A. Holt, Anna Waszkiewicz, Michael Klein, Timothy C. Jensen, Lorena Kallal Negron, Sharada Manns, Dwight M. Morrow, Linda S. Barton, Christina Pritchard, Jeffrey Guss, Jason W. Dodson, Robert N. Willette, Rusty E. Fries
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 23:4979-4984
Lead optimization of piperidine amide HTS hits, based on an anilino-thiazole core, led to the identification of analogs which displayed low nanomolar blocking activity at the canonical transient receptor channels 3 and 6 (TRPC3 & 6) based on FLIPR (c
Autor:
Alison I. Muir, Izzy Boyfield, Kalindi Vaidya, Barry Sidney Orlek, Etienne Fleury, David G. Evans, Jackie S. Scott, Hindy Mok, Victoria J. Bolton, Ward John Gerard, Geoffrey Stemp, Tom D. Heightman, Kim L. Matthews, Kirk Lawless, Gareth J. Sanger, Fiona McKay, Alexander J. Stevens, Emma M. Jarvie, James Matthew Bailey, Susan Marie Westaway, Mervyn Thompson, Jonathan B. Basilla
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 19:6452-6458
Optimisation of a series of benzazepine sulfonamide hit compounds identified from high throughput screening led to the discovery of a new series of tractable, potent motilin receptor agonists.